Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis

J Eur Acad Dermatol Venereol. 2023 Apr;37(4):e543-e546. doi: 10.1111/jdv.18804. Epub 2023 Jan 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Azetidines* / therapeutic use
  • Denmark
  • Dermatitis, Atopic* / drug therapy
  • Double-Blind Method
  • Humans
  • Immunosuppressive Agents
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • baricitinib
  • Immunosuppressive Agents
  • Azetidines

Grants and funding